Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration
9.7.2026 16:00:00 EEST | Business Wire | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S.
This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale.
“Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care team member, at the right time, to improve patient outcomes,” said Dr. Tim Showalter, Chief Medical Officer at Viz.ai. "This collaboration with Cortechs.ai extends that commitment into neurodegenerative disease, an area with profound unmet need and enormous potential—particularly where earlier patient identification and disease characterization can meaningfully change the treatment trajectory. We see this as the foundation for something much bigger, and we're just getting started."
With an established footprint of nearly 2,000 U.S. hospitals, Viz.ai is uniquely positioned alongside Cortechs.ai to ensure patients with neurodegenerative disease reach the right care, faster.
“Cortechs.ai is building NeuroQuant into the leading platform for neuro quantification and analysis by providing the trusted intelligence layer that enables healthcare innovators to seamlessly integrate clinically validated quantitative imaging into their own solutions,” said Kyle Frye, CEO at Cortechs.ai. “We believe the future of healthcare AI will be built on connected platforms, not isolated point solutions. Our partnership with Viz.ai is a powerful example of that vision, combining Viz.ai’s care coordination platform with the trusted quantitative insights of NeuroQuant and NeuroQuant MS platforms to accelerate innovation, enhance clinical decision-making, and ultimately improve outcomes for patients.”
Additional partnership and product announcements focused on neurodegenerative diseases are expected from Viz.ai in the near future, as the company continues to expand its AI-powered care coordination platform. For more information about Viz.ai and its growing portfolio of solutions, please visit Viz.ai.
About Viz.ai
Viz.ai is the leader in AI-powered care coordination and clinical workflow solutions, deployed in nearly 2,000 hospitals across the United States and trusted by leading life sciences companies. Its platform uniquely combines real-time, multimodal clinical data with deep clinician engagement to detect disease earlier, coordinate care teams, and help ensure patients receive the right treatment faster. Viz.ai was the first company to be awarded CMS reimbursement for AI and is ranked the #1 Healthcare AI Platform by hospitals and health systems in the Black Book Research survey. For more information, visit Viz.ai.
About Cortechs.ai
Cortechs.ai is a leader in AI applications in radiology. Cortechs.ai uses cutting-edge technologies in medical imaging to revolutionize disease screening and early detection so patients can enjoy longer, healthier lives. The company develops and markets breakthrough medical device software that quantifies and tracks neurodegenerative diseases and assists in the detection of clinically significant cancer. Cortechs.ai's industry-leading brain imaging software provides radiologists, neurologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective way to quantify brain structures for assessing Alzheimer's disease, epilepsy, multiple sclerosis, brain trauma, and other brain abnormalities. The company's numerous FDA-cleared products provide quantitative insights to help physicians with the diagnosis and follow-up of neurodegenerative and traumatic brain conditions, as well as prostate cancer. Please visit www.cortechs.ai for further information and follow us on Twitter, LinkedIn, and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260709990638/en/
Contacts
Media Contact
viz.ai@solcomms.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
Elliptic Announces Circle’s Participation in Agentic Design Partner Program9.7.2026 15:15:00 EEST | Press release
Elliptic, the global leader in digital asset intelligence, today announced that an affiliate of Circle Internet Group, Inc. (‘Circle’) (NYSE:CRCL) has joined its Agentic Design Partner Program, bringing together infrastructure providers, compliance teams, and technology leaders to help shape compliance solutions for autonomous, AI-driven financial activity. This momentum follows an investment from Circle Ventures, the corporate venture arm of Circle, and builds on a longstanding collaboration between the companies. Circle has been an Elliptic customer for multiple years and has expanded its use of Elliptic’s compliance capabilities across a range of digital asset initiatives. As stablecoins, tokenized assets, and AI-powered applications become increasingly integrated into financial services, new compliance challenges are emerging. Elliptic’s agentic compliance layer addresses these challenges by combining unique datasets, a scalable query platform and a set of agents that can detect an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom